The MHC Class II Transactivator (CIITA): A "Physiologic" Drug Against HIV-1 Replication

The MHC Class II Transactivator (CIITA): A "Physiologic" Drug Against HIV-1 Replication

Bibliographic Details
Main Authors:	Accolla Roberto S, Mortara Lorenzo, Barbaro Andrea, Tosi Giovanna
Format:	Article
Language:	English
Published:	BMC 2005-12-01
Series:	Retrovirology

Similar Items

7he MHC Class II Transactivator (CIITA): A Physiologic Inhibitor of HTLV-2 Retroviral Infection
by: Casoli Claudio, et al.
Published: (2005-12-01)

MHC class II transactivator CIITA inhibits Tax-2-mediated HTLV-2 LTR transactivation and viral replication by binding to, and affecting Tax-2 intracellular localization
by: Accolla Roberto S, et al.
Published: (2011-06-01)

The MHC-II transactivator CIITA, a viral restriction factor inhibiting the replication of Human T-Cell Lymphotropic Virus Type 1
by: Franchini Genoveffa, et al.
Published: (2011-06-01)

Protective anti-tumor vaccination against glioblastoma expressing the MHC class II transactivator CIITA
by: Fabrizio Celesti, et al.
Published: (2023-03-01)

The MHC-II Transactivator CIITA, a restriction factor against oncogenic HTLV-1 and HTLV-2 retroviruses: similarities and differences in the inhibition of Tax-1 and Tax-2 viral transactivators
by: Greta eForlani, et al.
Published: (2013-08-01)

Molecular and cellular correlates of the CIITA-mediated inhibition of HTLV-2 Tax-2 transactivator function resulting in loss of viral replication
by: Tosi Giovanna, et al.
Published: (2011-07-01)

Degradation, Promoter Recruitment and Transactivation Mediated by the Extreme N-Terminus of MHC Class II Transactivator CIITA Isoform III.
by: Yves B Beaulieu, et al.
Published: (2016-01-01)

The MHC Class II Transactivator CIITA: Not (Quite) the Odd-One-Out Anymore among NLR Proteins
by: Jorge Alfonso León Machado, et al.
Published: (2021-01-01)

Class II transactivator (CIITA) enhances cytoplasmic processing of HIV-1 Pr55Gag.
by: Kristen A Porter, et al.
Published: (2010-06-01)

Genomic mapping of the MHC transactivator CIITA using an integrated ChIP-seq and genetical genomics
by: Wong, D, et al.
Published: (2014)

CIITA-Driven MHC Class II Expressing Tumor Cells as Antigen Presenting Cell Performers: Toward the Construction of an Optimal Anti-tumor Vaccine
by: Roberto S. Accolla, et al.
Published: (2019-07-01)

Interaction analysis between HLA-DRB1 shared epitope alleles and MHC class II transactivator CIITA gene with regard to risk of rheumatoid arthritis.
by: Marcus Ronninger, et al.
Published: (2012-01-01)

A dual defensive role of CIITA against retroviral infections
by: Accolla Roberto, et al.
Published: (2006-12-01)

Unveiling the Hidden Treasury: CIITA-Driven MHC Class II Expression in Tumor Cells to Dig up the Relevant Repertoire of Tumor Antigens for Optimal Stimulation of Tumor Specific CD4+ T Helper Cells
by: Greta Forlani, et al.
Published: (2020-10-01)

Dysregulated recruitment of the histone methyltransferase EZH2 to the class II transactivator (CIITA) promoter IV in breast cancer cells.
by: Agnieszka D Truax, et al.
Published: (2012-01-01)

Role of PU.1 in MHC Class II Expression via CIITA Transcription in Plasmacytoid Dendritic Cells.
by: Ryosuke Miura, et al.
Published: (2016-01-01)

Class II transactivator induces expression of MHC-I and MHC-II in transmissible Tasmanian devil facial tumours
by: Chrissie E. B. Ong, et al.
Published: (2022-10-01)

CIITA and its dual roles in MHC gene transcription
by: Dinah S. Singer, et al.
Published: (2013-12-01)

Tripartite Motif 22 and Class II Transactivator Restriction Factors: Unveiling Their Concerted Action against Retroviruses
by: Greta Forlani, et al.
Published: (2017-10-01)

Tripartite Motif-Containing Protein 22 Interacts with Class II Transactivator and Orchestrates Its Recruitment in Nuclear Bodies Containing TRIM19/PML and Cyclin T1
by: Greta Forlani, et al.
Published: (2017-05-01)

Genomic Alterations in CIITA Are Frequent in Primary Mediastinal Large B Cell Lymphoma and Are Associated with Diminished MHC Class II Expression
by: Anja Mottok, et al.
Published: (2015-11-01)

CIITA-related block of HLA class II expression, upregulation of HLA class I, and heterogeneous expression of immune checkpoints in hepatocarcinomas: implications for new therapeutic approaches
by: Elise Ramia, et al.
Published: (2019-03-01)

NLRC5-CIITA Fusion Protein as an Effective Inducer of MHC-I Expression and Antitumor Immunity
by: Madanraj Appiya Santharam, et al.
Published: (2023-04-01)

The NLR member CIITA: Master controller of adaptive and intrinsic immunity and unexpected tool in cancer immunotherapy
by: Greta Forlani, et al.
Published: (2023-10-01)

Interferon Regulatory Factors 1 and 2 Play Different Roles in MHC II Expression Mediated by CIITA in Grass Carp, Ctenopharyngodon idella
by: Xiao-Bing Lu, et al.
Published: (2019-05-01)

Restriction factors in human retrovirus infections and the unprecedented case of CIITA as link of intrinsic and adaptive immunity against HTLV-1
by: Greta Forlani, et al.
Published: (2019-11-01)

The MHC Class-I Transactivator NLRC5: Implications to Cancer Immunology and Potential Applications to Cancer Immunotherapy
by: Akhil Shukla, et al.
Published: (2021-02-01)

NLRC5 exclusively transactivates MHC class I and related genes through a distinctive SXY module.
by: Kristina Ludigs, et al.
Published: (2015-03-01)

Boosting the MHC class II-restricted tumor antigen presentation to CD4+ T helper cells: a critical issue for triggering protective immunity and re-orienting the tumor microenvironment toward an anti-tumor state
by: Roberto eAccolla, et al.
Published: (2014-02-01)

Structural properties of MHC class II ligands, implications for the prediction of MHC class II epitopes.
by: Kasper Winther Jørgensen, et al.
Published: (2010-12-01)

MHC class I and class II structures.
by: Jones, E
Published: (1997)

Ligation of MHC Class II Induces PKC-Dependent Clathrin-Mediated Endocytosis of MHC Class II
by: Kento Masaki, et al.
Published: (2020-07-01)

MHC class II-alpha chain knockout mice support increased viral replication that is independent of their lack of MHC class II cell surface expression and associated immune function deficiencies.
by: Mohammed Alsharifi, et al.
Published: (2013-01-01)

MHC Class II Presentation in Autoimmunity
by: Irina A. Ishina, et al.
Published: (2023-01-01)

Organizing MHC Class II Presentation
by: David R Fooksman
Published: (2014-04-01)

Effect of Vitamin D on Experimental Autoimmune Neuroinflammation Is Dependent on Haplotypes Comprising Naturally Occurring Allelic Variants of CIITA (Mhc2ta)
by: Sonja Hochmeister, et al.
Published: (2020-11-01)

Limited Effects of Class II Transactivator-Based Immunotherapy in Murine and Human Glioblastoma
by: A. Katherine Tan, et al.
Published: (2023-12-01)

Preserved MHC class II antigen processing in monocytes from HIV-infected individuals.
by: Laila Woc-Colburn, et al.
Published: (2010-03-01)

Impact of MHC class I diversity on immune control of immunodeficiency virus replication.
by: Goulder, P, et al.
Published: (2008)

Methylation of class II transactivator gene promoter IV is not associated with susceptibility to Multiple Sclerosis
by: Ramagopalan, S, et al.
Published: (2008)